Ann Oncol：老年肺癌患者术后化疗不影响生存质量

　　韩国学者的一项研究显示，老年非小细胞肺癌（NSCLC）患者可能存在其它共存病，以及身体机能下降，术后的辅助化疗对老年病人的健康相关生存质量（HRQOL）无显著影响，且治疗前后的HRQOL无显著差别。

　　该研究于2008年10月到2011年10月期间纳入65岁以上（N=66）和65以下（N=73）的NSCLC患者，比较其化疗后的HRQOL。

　　结果显示，术后的辅助化疗对老年病人的健康相关生存质量（HRQOL）无显著影响，且治疗前后的HRQOL无显著差别。

Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer.
BACKGROUND
Given the more comorbidities with a decline in physiologic reserve, it can be challenging to make appropriate treatment decisions in the elderly.
PATIENTS AND METHODS
Here, we prospectively evaluated and compared the health-related quality of life (HRQOL) of patients aged ≥65 with aged <65 who were treated with a postoperative chemotherapy for completely resected stage Ib, II or IIIa non-small-cell lung cancer (NSCLC). Either four cycles of paclitaxel (Taxol)-carboplatin (PC) or vinorelbine-cisplatin (NP) was used. The HRQOL was assessed with EORTC QLQ-C30 and EORTC QLQ-LC13.
RESULTS
Between October 2008 and October 2011, a total of 139 patients (aged <65, n = 73; ≥65, n = 66) were enrolled, and 127 (91.4%) completed the questionnaire. Overall, the quality of life (QOL) in elderly patients did not significantly deteriorate with adjuvant chemotherapy and the time trend of QOL in elderly patients was similar to that of younger patients. Although the elderly suffered from increased treatment-related adverse events involving sore mouth, peripheral neuropathy and alopecia compared with the baseline, the same time trends were also observed in younger group. The mean dose intensities (MDIs) for PC and NP regimen were not significantly different between the two age groups.
CONCLUSIONS
Postoperative chemotherapy did not substantially reduce HRQOL in elderly NSCLC patients, and HRQOL during and after adjuvant chemotherapy did not significantly differ by age.